Business

Arrhythmia’s quarterly loss widens

A plastinated human heart was displayed at a European cardiology conference.

Reuters/File 2013

A plastinated human heart was displayed at a European cardiology conference.

Arrhythmia Research Technology Inc.’s quarterly net loss widened to $2.89 million, or $1.06 per share, from $1.04 million, or 37 cents, in the same quarter last year. But the Fitchburg company’s total consolidated revenue from continuing operations grew 1.8 percent, to $4.88 million, from a year before. The company and its Micron Products subsidiary supply products for the medical and defense industries, including software to detect certain heart arrhythmias.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.